EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction

Ali A Rabaan iD, Hajir AlSaihati iD, Rehab Bukhamsin, Muhammed A Bakhrebah iD, Majed S Nassar iD, Abdulmonem A Alsaleh iD, Yousef N Alhashem iD, Ammar Y Bukhamseen, Khalil Al-Ruhimy, Mohammed Alotaibi, Roua A Alsubki iD, Hejji E Alahmed und 9 weitere

Current Oncology · 06.02.2023 · 30 (2) · 1954-1976

DOI: 10.3390/curroncol30020152 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 06.02.2023. Verfasst von Ali A Rabaan und 20 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Neoplasms. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 222 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene editing, especially with clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9), has advanced gene function science. Gene editing’s rapid advancement has increased its medical/clinical value. Due to its great specificity and efficiency, CRISPR/Cas9 can accurately and swiftly screen the whole genome. This simplifies disease-specific gene therapy. To study tumor origins, development, and metastasis, CRISPR/Cas9 can change genomes. In recent years, tumor treatment research has increasingly employed this method. CRISPR/Cas9 can treat cancer by removing genes or correcting mutations. Numerous preliminary tumor treatment studies have been conducted in relevant fields. CRISPR/Cas9 may treat gene-level tumors. CRISPR/Cas9-based personalized and targeted medicines may shape tumor treatment. This review examines CRISPR/Cas9 for tumor therapy research, which will be helpful in providing references for future studies on the pathogenesis of malignancy and its treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsNeoplasmsHumansGene EditingGenetic TherapyPhenotype

Stichwörter der Autor:innen

CRISPR/Casadvanced technologiesadvanced therapeuticscancercancer treatmentclinical trialsoncoviruses

Autor:innen und Institutionen

  • Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.
  • College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
  • Department of Public Health and Nutrition, The University of Haripur, Haripur 22610, Pakistan.
  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafr Al Batin 39831, Saudi Arabia.
  • Dammam Regional Laboratory and Blood Bank, Dammam 31411, Saudi Arabia.
  • Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.

ORCID-Profile: Ali A Rabaan, Hajir AlSaihati, Muhammed A Bakhrebah, Majed S Nassar, Abdulmonem A Alsaleh, Yousef N Alhashem, Roua A Alsubki, Saleh Al-Abdulhadi, Ramadan Abdelmoez Farahat, Mohd Imran, Ranjan K Mohapatra

Zitieren

APA

Rabaan, A. A., AlSaihati, H., Bukhamsin, R., Bakhrebah, M. A., Nassar, M. S., Alsaleh, A. A., Alhashem, Y. N., Bukhamseen, A. Y., Al-Ruhimy, K., Alotaibi, M., Alsubki, R. A., Alahmed, H. E., Al-Abdulhadi, S., Alhashem, F. A., Alqatari, A. A., Alsayyah, A., Farahat, R. A., Abdulal, R. H., Al-Ahmed, A. H., …, & Mohapatra, R. K. (2023). Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction. Current Oncology, 30(2), 1954-1976. https://doi.org/10.3390/curroncol30020152

Vancouver

Rabaan AA, AlSaihati H, Bukhamsin R, Bakhrebah MA, Nassar MS, Alsaleh AA, et al. Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction. Current Oncology. 2023;30(2):1954-1976. doi:10.3390/curroncol30020152

BibTeX
@article{Rabaan2023,
  author = {Rabaan, Ali A and AlSaihati, Hajir and Bukhamsin, Rehab and Bakhrebah, Muhammed A and Nassar, Majed S and Alsaleh, Abdulmonem A and Alhashem, Yousef N and Bukhamseen, Ammar Y and Al-Ruhimy, Khalil and Alotaibi, Mohammed and Alsubki, Roua A and Alahmed, Hejji E and Al-Abdulhadi, Saleh and Alhashem, Fatemah A and Alqatari, Ahlam A and Alsayyah, Ahmed and Farahat, Ramadan Abdelmoez and Abdulal, Rwaa H and Al-Ahmed, Ali H and Imran, Mohd and Mohapatra, Ranjan K},
  title = {Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {2},
  pages = {1954--1976},
  doi = {10.3390/curroncol30020152}
}
Kostenlos starten →